Long term outcomes of patients with chronic kidney disease after COVID-19 in an urban population in the Bronx

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 19, 2025

Abstract We investigated the long-term kidney and cardiovascular outcomes of patients with chronic disease (CKD) after COVID-19. Our retrospective cohort consisted 834 CKD COVID-19 6,167 without between 3/11/2020 to 7/1/2023. Multivariate competing risk regression models were used estimate (as adjusted hazard ratios (aHR) 95% confidence intervals (CI)) progression a more advanced stage (Stage 4 or 5) major adverse events (MAKE), (MACE) at 6-, 12-, 24-month follow up. Hospitalized 12 24 months (aHR 1.62 CI[1.24,2.13] 1.76 [1.30, 2.40], respectively), but not non-hospitalized patients, higher compared those Both hospitalized MAKE 12- 24-months 1.73 [1.21, 2.50], 1.77 [1.34, 2.33], 1.31 [1.05, 1.64], MACE increases in CKD. These findings highlight need for close up care therapies that slow this high-risk subgroup.

Language: Английский

---

Incidence of new-onset hypertension before, during, and after the COVID-19 pandemic: a 7-year longitudinal cohort study in a large population

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: March 19, 2024

Abstract Background While the augmented incidence of diabetes after COVID-19 has been widely confirmed, controversial results are available on risk developing hypertension during pandemic. Methods We designed a longitudinal cohort study to analyze closed followed up over 7-year period, i.e., 3 years before and pandemic, 2023, when pandemic was declared be over. analyzed medical records more than 200,000 adults obtained from cooperative primary physicians January 1, 2017, December 31, 2023. The main outcome new diagnosis hypertension. Results evaluated 202,163 individuals in pre-pandemic 190,743 years, totaling 206,857 including 2023 data. rate 2.11 (95% C.I. 2.08–2.15) per 100 person-years 2017–2019, increasing 5.20 5.14–5.26) period 2020–2022 (RR = 2.46), 6.76 6.64–6.88) marked difference trends between first two successive observation periods substantiated by fitted regression lines Poisson models conducted monthly log-incidence Conclusions detected significant increase new-onset which at end affected ~ 20% studied cohort, percentage higher infection within same time frame. This suggests that increased attention screening should not limited who aware having contracted but extended entire population.

Language: Английский

---

Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis

Diagnostics, Journal Year: 2024, Volume and Issue: 14(6), P. 621 - 621

Published: March 14, 2024

While ground-glass opacity, consolidation, and fibrosis in the lungs are some of hallmarks acute SAR-CoV-2 infection, it remains unclear whether these pulmonary radiological findings would resolve after symptoms have subsided. We conducted a systematic review meta-analysis to evaluate chest computed tomography (CT) abnormalities stratified by COVID-19 disease severity multiple timepoints post-infection. PubMed/MEDLINE was searched for relevant articles until 23 May 2023. Studies with COVID-19-recovered patients follow-up CT at least 12 months post-infection were included. evaluated short-term (1–6 months) long-term (12–24 follow-ups (severe non-severe). A generalized linear mixed-effects model random effects used estimate event rates findings. total 2517 studies identified, which 43 met inclusion (N = 8858 patients). Fibrotic-like changes had highest rate (0.44 [0.3–0.59]) (0.38 [0.23–0.56]) follow-ups. meta-regression showed that over time decreased any abnormality (β −0.137, p 0.002), opacities −0.169, < 0.001), increased honeycombing 0.075, 0.03), did not change fibrotic-like changes, bronchiectasis, reticulation, interlobular septal thickening (p > 0.05 all). The severe subgroup significantly higher bronchiectasis 0.02), reticulation 0.001) when compared non-severe subgroup. In conclusion, significant remained up 2 years post-COVID-19, especially disease. Long-lasting post-SARS-CoV-2 infection signal future public health concern, necessitating extended monitoring, rehabilitation, survivor support, vaccination, ongoing research targeted therapies.

Language: Английский

---

Vascular Alterations Following COVID-19 Infection: A Comprehensive Literature Review

Life, Journal Year: 2024, Volume and Issue: 14(5), P. 545 - 545

Published: April 24, 2024

SARS-CoV-2, the causative agent of ongoing COVID-19 pandemic, has revealed a broader impact beyond respiratory system, predominantly affecting vascular system with various adverse manifestations. The infection induces endothelial dysfunction and immune dysregulation, creating an inflammatory hypercoagulable state. It affects both microvasculature macrovasculature, leading to thromboembolic events, cardiovascular manifestations, impaired arterial stiffness, cerebrovascular complications, nephropathy, as well retinopathy-frequently observed in cases severe illness. Evidence suggests that SARS-CoV-2 may result persistent effects on identified long-term COVID-19. This is characterized by prolonged inflammation, endotheliopathy, increased risk complications. Various imaging modalities, histopathological studies, diagnostic tools such video capillaroscopy magnetic resonance have been employed visualize alterations. review aims comprehensively summarize evidence concerning short alterations following infection, investigating their patients' prognosis, providing overview preventive strategies mitigate associated

Language: Английский

---

Long COVID: Long-Term Impact of SARS-CoV2

Diagnostics, Journal Year: 2024, Volume and Issue: 14(7), P. 711 - 711

Published: March 28, 2024

Four years post-pandemic, SARS-CoV-2 continues to affect many lives across the globe. An estimated 65 million people suffer from long COVID, a term used encapsulate post-acute sequelae of infections that multiple organ systems. Known symptoms include chronic fatigue syndrome, brain fog, cardiovascular issues, autoimmunity, dysautonomia, and clotting due inflammation. Herein, we review COVID symptoms, proposed theories behind pathology, diagnostics, treatments, clinical trials underway explore treatments for viral persistence, autonomic cognitive dysfunctions, sleep disturbances, fatigue, exercise intolerance.

Language: Английский

---

Patients with unmet social needs are at higher risks of developing severe long COVID-19 symptoms and neuropsychiatric sequela

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: April 2, 2024

Abstract This study investigated long COVID of patients in the Montefiore Health System COVID-19 (CORE) Clinics Bronx with an emphasis on identifying health related social needs (HRSNs). We analyzed a cohort 643 CORE (6/26/2020–2/24/2023) and 52,089 non-CORE patients. Outcomes included symptoms, physical, emotional, cognitive function test scores obtained at least three months post-infection. Socioeconomic variables median incomes, insurance status, HRSNs. The was older age (53.38 ± 14.50 vs. 45.91 23.79 years old, p < 0.001), more female (72.47% 56.86%, had higher prevalence hypertension (45.88% 23.28%, diabetes (22.86% 13.83%, COPD (7.15% 2.28%, asthma (25.51% 12.66%, lower incomes (53.81% 43.67%, 1 st quintile, unmet (29.81% 18.49%, 0.001) compared to survivors. reported wide range severe long-COVID symptoms. HRSNs experienced worse ESAS-r (tiredness, wellbeing, shortness breath, pain), PHQ-9 (12.5 (6, 17.75) 7 (2, 12), GAD-7 (8.5 (3, 15) 4 (0, 9), without. Patients outcomes those

Language: Английский

---

Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment

PLoS Medicine, Journal Year: 2024, Volume and Issue: 21(4), P. e1004263 - e1004263

Published: April 4, 2024

Background Acute neurological manifestation is a common complication of acute Coronavirus Disease 2019 (COVID-19) disease. This retrospective cohort study investigated the 3-year outcomes patients with and without significant manifestations during initial COVID-19 hospitalization. Methods findings Patients hospitalized for Severe Respiratory Syndrome 2 (SARS-CoV-2) infection between 03/01/2020 4/16/2020 in Montefiore Health System Bronx, an epicenter early pandemic, were included. Follow-up data was captured up to 01/23/2023 (3 years post-COVID-19). consisted 414 1,199 propensity-matched (for age severity score) manifestations. Neurological involvement phase included stroke, new or recrudescent seizures, anatomic brain lesions, presence altered mentation evidence impaired cognition arousal, neuro-COVID-19 complex (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, paresthesias, cranial nerve abnormalities, ataxia, dysautonomia, skeletal muscle injury normal orientation arousal signs). There no group differences female sex composition (44.93% versus 48.21%, p = 0.249), ICU IMV status, white, not Hispanic (6.52% 7.84%, 0.380), (33.57% 38.20%, 0.093), except black non-Hispanic (42.51% 36.03%, 0.019). Primary mortality, heart attack, major adverse cardiovascular events (MACE), reinfection, hospital readmission post-discharge. Secondary neuroimaging (hemorrhage, active prior mass effect, microhemorrhages, white matter changes, microvascular disease (MVD), volume loss). More discharged rehabilitation (10.39% 3.34%, < 0.001) skilled nursing facilities (35.75% 25.35%, fewer home (50.24% 66.64%, than matched controls. Incidence any reason (65.70% 60.72%, 0.036), stroke (6.28% 2.34%, 0.001), MACE (20.53% 16.51%, 0.032) higher Per Kaplan–Meier univariate survival curve analysis, such more likely die post-discharge compared controls (hazard ratio: 2.346, (95% confidence interval (CI) [1.586, 3.470]; 0.001)). Across both cohorts, causes death (13.79% neurological, 15.38% control), sepsis (8.63%, 17.58%), influenza pneumonia (13.79%, 9.89%), (10.34%, 7.69%), respiratory distress syndrome (ARDS) 6.59%). Factors associated mortality after leaving involved (odds ratio (OR): 1.802 CI [1.237, 2.608]; 0.002)), discharge disposition (OR: 1.508 [1.276, 1.775]; 0.001)), congestive failure 2.281 [1.429, 3.593]; score 1.177 [1.062, 1.304]; older 1.027 [1.010, 1.044]; 0.002)). radiological findings, that showed significantly age-adjusted loss ( 0.045) The study’s patient limited infected first wave when hospitals overburdened, vaccines yet available, treatments limited. Patient profiles might differ interrogating subsequent waves. Conclusions had worse long-term These raise awareness need closer monitoring timely interventions manifestations, as their course involving enhanced morbidity mortality.

Language: Английский

---

Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall–Winter 2022–2023: A Cross-Sectional Retrospective Study

Diseases, Journal Year: 2024, Volume and Issue: 12(1), P. 16 - 16

Published: Jan. 3, 2024

Influenza and COVID-19 contribute significantly to the infectious disease burden during respiratory season, but their relative remains unknown. This study characterizes frequency severity of medically attended influenza peak 2022–2023 season in pediatric, adult, older adult populations prevalence underlying conditions among patients hospitalized with COVID-19. cross-sectional analysis included individuals Veradigm EHR Database linked Komodo claims data a medical encounter between 1 October 2022 31 March 2023 (study period). Patients encounters were identified diagnosis or period stratified based on highest level care received that diagnosis. Among 23,526,196 individuals, there more COVID-19-related than influenza-related encounters, overall by outcome. Hospitalizations common hospitalizations (incidence ratio = 4.6) all age groups. Nearly adults had at least one condition, 37.1% 0–5-year-olds 25.0% 6–17-year-olds no conditions. was associated greater season.

Language: Английский

---

SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population

Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 86, P. 105613 - 105613

Published: April 8, 2024

Language: Английский

---

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States

Journal of Medical Economics, Journal Year: 2023, Volume and Issue: 26(1), P. 1532 - 1545

Published: Nov. 14, 2023

Aims To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA vaccines updated for fall 2023 in adults ≥18 years over a 1-year analytic time horizon (September 2023-August 2024).

Language: Английский

---